NCT04229030: A trial that was reported late by Raziel Therapeutics Ltd.
This trial has reported, although it was 667 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT04229030 |
|---|---|
| Title | A Double Blind, Randomized, Multi-Center, Placebo-Controlled Phase 2B Clinical Trial for the Evaluation of Efficacy and Safety of RZL-012 in Subjects Having Dercum's Disease Lipomas |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | July 30, 2020 |
| Completion date | Feb. 20, 2021 |
| Required reporting date | Feb. 20, 2022, midnight |
| Actual reporting date | Dec. 19, 2023 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | 667 |